Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNPHENY-3
2022-502932-37-00Phase 3Completed
- Sponsor
- Synlogic
- Start
- Jan 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of labafenogene marselecobac in phenylketonuria (PKU) (4 arms), sponsored by Synlogic. Primary endpoints: Percent change from baseline in blood phenylalanine at last measurement of the individually titrated dose, Change from baseline to Week 4 in blood phenylalanine and 3 more. Started Jan 2024; status: completed.
02
Drugs
labafenogene marselecobac
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on 2022-502932-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502932-37-00.